JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on August 11, 2008; DOI: 10.1124/jpet.108.140145


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.108.140145v1
327/2/393    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Kim, B. H.
Right arrow Articles by Kim, Y.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, B. H.
Right arrow Articles by Kim, Y.


Received for publication April 18, 2008.
Revised July 22, 2008.
Accepted for publication August 8, 2008.

Diarctigenin, a Lignan Constituent from Arctium lappa, Down-Regulated Zymosan-Induced Transcription of Inflammatory Genes through Suppression of DNA Binding Ability of Nuclear Factor-{kappa}B in Macrophages

Byung Hak Kim 1, Seong Su Hong 1, Soon Woo Kwon 1, Hwa Young Lee 1, Hyeran Sung 1, In-Jeong Lee 1, Bang Yeon Hwang 2, Sukgil Song 1, Chong-Kil Lee 1, Daehyun Chung 1, Byeongwoo Ahn 1, Sang-Yoon Nam 1, Sang-Bae Han 1, Youngsoo Kim 1*

1 Chungbuk National University 2 Chungnam National University

* Address correspondence to: E-mail: youngsoo{at}chungbuk.ac.kr

Abstract

Diarctigenin was previously isolated as an inhibitor of nitric oxide (NO) production in macrophages, from the seeds of Arctium lappa used as an alternative medicine for the treatment of inflammatory disorders. However, little is known about the molecular basis of these effects. Here, we demonstrated that diarctigenin inhibited the production of NO, prostaglandin E2, tumor necrosis factor-{alpha}, interleukin (IL)-1{beta} and IL-6 with IC50 values of 6-12 µM in zymosan- or lipopolysaccharide (LPS)-activated macrophages. Diarctigenin attenuated zymosan-induced mRNA synthesis of inducible NO synthase (iNOS) and also inhibited promoter activities of iNOS and cytokine genes in the cells. Since nuclear factor (NF)-{kappa}B plays a pivotal role in inflammatory gene transcription, we next investigated the effect of diarctigenin on NF-{kappa}B activation. Diarctigenin inhibited the transcriptional activity and DNA binding ability of NF-{kappa}B in zymosan-activated macrophages, but did not affect the degradation and phosphorylation of inhibitory {kappa}B (I{kappa}B) proteins. Moreover, diarctigenin suppressed expression vector NF-{kappa}B p65-elicited NF-{kappa}B activation and also iNOS promoter activity, indicating that the compound could directly target an NF-{kappa}B activating signal cascade downstream of I{kappa}B degradation and inhibit NF-{kappa}B-regulated iNOS expression. Diarctigenin also inhibited the in vitro DNA binding ability of NF-{kappa}B but did not affect the nuclear import of NF-{kappa}B p65 in the cells. Taken together, diarctigenin down-regulated zymosan- or LPS-induced inflammatory gene transcription in macrophages, which was due to direct inhibition of the DNA binding ability of NF-{kappa}B. Finally, this study provides a pharmacological potential of diarctigenin in the NF-{kappa}B-associated inflammatory disorders.


Key words: Anti-inflammatory potential, Arctium lappa, Diarctigenin, Inflammatory gene transcription, Lignan compound, NF-kB activation





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.